Skip to main content

$1.14 -0.01 (-0.44%)

High

$1.17

Low

$1.13

Trades

1,304

Turnover

$2,983,889

Volume

2,606,681
30 June 2023 at 4:10pm
Register to track MSB and receive email alerts.

FDAs OTAT Agrees to Primary Endpoint for Back Pain

StockBot

416,823 posts

MSB released this announcement to the ASX on 16 December 2021, 10:08. The announcement is marked as price sensitive, and is 3 page(s) in length and 171.73kb in size.

You can view all announcements from MSB and see how they appear on a price chart on the announcements page.

At the date of this announcement, MSB was 9.057% short sold according to ASIC data. It was ranked the 6th most shorted stock on the ASX. It remains ranked 40th as of the latest reported data (05 May 2025).

Other Recent Announcements from MSB
Change of Director's Interest Notice 13 June 2023, 8:56
Mesoblast Director Appointed to Strategic Advisory Role 5 June 2023, 9:41
MSB Reports Q3 Financial Results and Operational Highlights 26 May 2023, 8:32
FDAs OTAT Agrees to Primary Endpoint for Back Pain 16 December 2021, 10:08
Update on Novartis Agreement 14 December 2021, 10:30
Pause in Trading 14 December 2021, 9:47
Rexlemestrocel Greatest Benefit in Diabetics and Ischemics 6 December 2021, 10:00
You must login or register to post a comment.

You must be logged in to post a reply.

Register to track MSB and receive email alerts.